Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Applies In Japan For First Global Approval Of Type 2 Diabetes Drug

This article was originally published in PharmAsia News

Executive Summary

Sanofi filed an application in Japan for the world's first approval of its Lyxumia (lixisenetide) for treating type 2 diabetes.

You may also be interested in...



Sun, Accord, Amneal And Apotex Donate Hydroxychloroquine

Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

Switzerland Approves Raft Of Rx-To-OTC Switches

Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.

Topics

Related Companies

UsernamePublicRestriction

Register

SC081350

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel